Coherus Biosciences (NASDAQ:CHRS) was upgraded by research analysts at TheStreet from a “d-” rating to a “c-” rating in a research note issued on Thursday, TheStreetRatingsTable reports.
Several other equities analysts have also weighed in on the stock. Maxim Group reissued a “buy” rating and issued a $27.00 price objective (up from $25.00) on shares of Coherus Biosciences in a research report on Friday, August 2nd. Credit Suisse Group reissued a “buy” rating and issued a $36.00 price objective on shares of Coherus Biosciences in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective (up from $28.00) on shares of Coherus Biosciences in a research report on Friday, August 2nd. Zacks Investment Research raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Thursday. Finally, Mizuho set a $43.00 price objective on shares of Coherus Biosciences and gave the company a “buy” rating in a research report on Sunday, September 29th. Two analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Coherus Biosciences presently has an average rating of “Buy” and an average price target of $30.38.
NASDAQ CHRS traded up $0.06 during trading on Thursday, reaching $19.06. 1,353,200 shares of the stock traded hands, compared to its average volume of 992,812. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -5.92 and a beta of 2.90. The stock’s 50-day moving average price is $19.20 and its 200 day moving average price is $19.18. Coherus Biosciences has a fifty-two week low of $8.32 and a fifty-two week high of $23.91.
In related news, COO Vincent R. Anicetti sold 2,500 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $20.03, for a total transaction of $50,075.00. Following the transaction, the chief operating officer now directly owns 21,810 shares of the company’s stock, valued at $436,854.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Jean-Frederic Viret sold 1,388 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $19.02, for a total transaction of $26,399.76. Following the transaction, the chief financial officer now directly owns 6,385 shares in the company, valued at $121,442.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,264 shares of company stock worth $504,967. 18.20% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the business. Cutler Group LP acquired a new stake in Coherus Biosciences during the third quarter worth about $32,000. Tower Research Capital LLC TRC acquired a new stake in Coherus Biosciences during the third quarter worth about $52,000. Public Employees Retirement System of Ohio acquired a new stake in Coherus Biosciences during the second quarter worth about $75,000. Aperio Group LLC acquired a new stake in Coherus Biosciences during the second quarter worth about $80,000. Finally, Bank of Montreal Can acquired a new stake in Coherus Biosciences during the second quarter worth about $114,000. Hedge funds and other institutional investors own 96.37% of the company’s stock.
About Coherus Biosciences
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Read More: What is Put Option Volume?
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.